Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

“The body of evidence for the GLP-1 drug class shows that up to 40% of total weight loss in GLP-1 patients ... levels in patients receiving the GLP-1 agonist Wegovy® or Ozempic® who show ...